-+ 0.00%
-+ 0.00%
-+ 0.00%

Amgen Discontinuing Future Development Of AMG 513; To Continue Phase 1 Trial Of AMG 513 In Adults With Obesity

Benzinga·08/04/2026 20:59:48
語音播報

Amgen (NASDAQ: AMGN) today announced it will discontinue Future development of AMG 513. A Phase 1 study of AMG 513 in adults living with obesity will remain ongoing to follow enrolled participants through completion of the study.